title: Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients.
abstract: BACKGROUND
  Genital herpes is caused by herpes simplex virus 1 (HSV-1) or 2 (HSV-2). Some infected people experience outbreaks of genital herpes, typically, characterized by vesicular and erosive localized painful genital lesions.
  
  
  OBJECTIVE
  To compare the effectiveness and safety of three oral antiviral drugs (acyclovir, famciclovir and valacyclovir) prescribed to suppress genital herpes outbreaks in non-pregnant patients.
  
  
  METHODS
  We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the search portal of the World Health Organization International Clinical Trials Registry Platform and pharmaceutical company databases up to February 2014. We also searched US Food and Drug Administration databases and proceedings of seven congresses to a maximum of 10 years. We contacted trial authors and pharmaceutical companies.
  
  
  METHODS
  We selected parallel-group and cross-over randomized controlled trials including patients with recurrent genital herpes caused by HSV, whatever the type (HSV-1, HSV-2, or undetermined), with at least four recurrences per year (trials concerning human immunodeficiency virus (HIV)-positive patients or pregnant women were not eligible) and comparing suppressive oral antiviral treatment with oral acyclovir, famciclovir, and valacyclovir versus placebo or another suppressive oral antiviral treatment.
  
  
  METHODS
  Two review authors independently selected eligible trials and extracted data. The Risk of bias tool was used to assess risk of bias. Treatment effect was measured by the risk ratio (RR) of having at least one genital herpes recurrence. Pooled RRs were derived by conventional pairwise meta-analyses. A network meta-analysis allowed for estimation of all possible two-by-two comparisons between antiviral drugs.
  
  
  RESULTS
  A total of 26 trials (among which six had a cross-over design) were included. Among the 6950 randomly assigned participants, 54% (range 0 to 100%) were female, mean age was 35 years (range 26 to 45.1), and the mean number of recurrences per year was 11 (range 6.3 to 17.8). Duration of treatment was two to 12 months. Risk of bias was considered high for half of the studies and unclear for the other half. A total of 14 trials compared acyclovir versus placebo, four trials compared valacyclovir versus placebo and 2 trials compared valacyclovir versus no treatment. Three trials compared famciclovir versus placebo. Two trials compared valacyclovir versus famciclovir and one trial compared acyclovir versus valacyclovir versus placebo.We analyzed data from 22 trials for the outcome: risk of having at least one clinical recurrence. We could not obtain the outcome data for four trials. In placebo-controlled trials, there was a low quality evidence that the risk of having at least one clinical recurrence was reduced with acyclovir (nine parallel-group trials, n = 2049; pooled RR 0.48, 95% confidence interval (CI) 0.39 to 0.58), valacyclovir (four trials, n = 1788; pooled RR 0.41, 95% CI 0.24 to 0.69), or famciclovir (two trials, n = 732; pooled RR 0.57, 95% CI 0.50 to 0.64). The six cross-over trials showed larger treatment effects on average than the parallel-group trials. We found evidence of a small-study effect for acyclovir placebo-controlled trials (adjusted pooled RR 0.61, 95% CI 0.49 to 0.75). In analyzing parallel-group trials by daily dose, no clear evidence was found of a dose-response relationship for any drug. In head-to-head trials, the risk of having at least one recurrence was increased with valacyclovir rather than acyclovir (one trial, n = 1345; RR 1.16, 95% CI 1.01 to 1.34) and was not significantly different from that seen with famciclovir as compared with valacyclovir (one trial, n = 320; RR 1.18, 95% CI 0.86 to 1.63).We included 16 parallel-arm trials in a network meta-analysis and we were unable to determine which of the drugs was most effective in reducing the risk of at least one clinical recurrence (after adjustment for small-study effects, pooled RR 0.83, 95% CI 0.61 to 1.11 for valacyclovir vs acyclovir; pooled RR 1.04, 95% CI, 0.71 to 1.49 for famciclovir vs acyclovir; and pooled RR 1.26, 95% CI 0.89 to 1.75 for famciclovir vs valacyclovir). Safety data were sought but were reported as total numbers of adverse events.
  
  
  CONCLUSIONS
  Owing to risk of bias and inconsistency, there is low quality evidence that suppressive antiviral therapy with acyclovir, valacyclovir or famciclovir in pacients experiencing at least four recurrences of genital herpes per year decreases the number of pacients with at least one recurrence as compared with placebo. Network meta-analysis of the few direct comparisons and the indirect comparisons did not show superiority of one drug over another.
authors.affiliation: Department of Dermatology, Hôpital Henri Mondor, 51 avenue du Général de Lattre de Tassigny, Créteil, France, 94010.
authors.forename: Laurence
authors.initials: L
authors.lastname: Le Cleach
authors.forename: Ludovic
authors.initials: L
authors.lastname: Trinquart
authors.forename: Giao
authors.initials: G
authors.lastname: Do
authors.forename: Annabel
authors.initials: A
authors.lastname: Maruani
authors.forename: Benedicte
authors.initials: B
authors.lastname: Lebrun-Vignes
authors.forename: Philippe
authors.initials: P
authors.lastname: Ravaud
authors.forename: Olivier
authors.initials: O
authors.lastname: Chosidow
mesh_terms: D015075:2-Aminopurine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000212:Acyclovir / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D000284:Administration, Oral; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D000077595:Famciclovir; D005260:Female; D006558:Herpes Genitalis / Q000517:prevention & control* / Q000821:virology; D018259:Herpesvirus 1, Human; D018258:Herpesvirus 2, Human; D006801:Humans; D007121:Immunocompetence; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D000077483:Valacyclovir; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000998:Antiviral Agents; D015075:2-Aminopurine; D014633:Valine; D000077483:Valacyclovir; D000077595:Famciclovir; D000212:Acyclovir
references.citation: G Ital Chemioter. 1991 Jan-Dec;38(1-3):61-2
references.pmid: 1365612
references.citation: J Am Acad Dermatol. 1986 Aug;15(2 Pt 1):256-64
references.pmid: 3745529
references.citation: Clin Infect Dis. 2005 Oct 15;41(8):1097-104
references.pmid: 16163627
references.citation: J Antimicrob Chemother. 1999 Oct;44(4):525-31
references.pmid: 10588314
references.citation: BMC Med Res Methodol. 2012 Sep 27;12:150
references.pmid: 23016799
references.citation: Lancet. 2008 Jun 21;371(9630):2109-19
references.pmid: 18572080
references.citation: Arch Intern Med. 1997 Feb 10;157(3):343-9
references.pmid: 9040303
references.citation: Bull World Health Organ. 2008 Oct;86(10):805-12, A
references.pmid: 18949218
references.citation: Rev Med Chil. 1991 Aug;119(8):876-80
references.pmid: 1668960
references.citation: Lancet. 2007 Dec 22;370(9605):2127-37
references.pmid: 18156035
references.citation: J Infect Dis. 2004 Apr 15;189(8):1341-7
references.pmid: 15073669
references.citation: Dermatologica. 1986;173(5):220-3
references.pmid: 3100353
references.citation: J Infect Dis. 1998 Sep;178(3):603-10
references.pmid: 9728526
references.citation: J Infect Dis. 1991 Oct;164(4):753-7
references.pmid: 1894936
references.citation: CMAJ. 2007 Apr 10;176(8):1091-6
references.pmid: 17420491
references.citation: J Med Virol. 1998 Jun;55(2):177-83
references.pmid: 9598940
references.citation: Sex Transm Dis. 2003 Feb;30(2):174-7
references.pmid: 12567178
references.citation: Clin Infect Dis. 2002 Apr 1;34(7):944-8
references.pmid: 11880960
references.citation: J Infect Dis. 2010 Apr 15;201(8):1164-8
references.pmid: 20214474
references.citation: J Antimicrob Chemother. 1985 Aug;16(2):219-26
references.pmid: 3905750
references.citation: Clin Infect Dis. 2006 Jan 1;42(1):8-13
references.pmid: 16323085
references.citation: Sex Transm Dis. 2007 May;34(5):297-301
references.pmid: 16960547
references.citation: Clin Pharm. 1982 Sep-Oct;1(5):399-406
references.pmid: 6307582
references.citation: Clin Infect Dis. 2004 Nov 1;39 Suppl 5:S258-66
references.pmid: 15494897
references.citation: Arch Intern Med. 2009 Jul 13;169(13):1233-40
references.pmid: 19597073
references.citation: N Engl J Med. 2008 Apr 10;358(15):1560-71
references.pmid: 18337596
references.citation: Am J Med. 1988 Aug 29;85(2A):30-3
references.pmid: 3044089
references.citation: Sex Transm Dis. 2003 Mar;30(3):226-31
references.pmid: 12616141
references.citation: JAMA. 1998 Sep 9;280(10):887-92
references.pmid: 9739972
references.citation: Lancet. 1988 Apr 23;1(8591):926-8
references.pmid: 2895840
references.citation: Lancet. 2012 Feb 18;379(9816):641-7
references.pmid: 22225814
references.citation: Dan Med Bull. 1989 Jun;36(3):298-300
references.pmid: 2666040
references.citation: Sex Transm Dis. 2007 Nov;34(11):900-7
references.pmid: 17538513
references.citation: JAMA. 1991 Feb 13;265(6):747-51
references.pmid: 1990191
references.citation: Am J Med. 1988 Aug 29;85(2A):14-9
references.pmid: 3044076
references.citation: Lancet. 1984 Jul 14;2(8394):57-9
references.pmid: 6146006
references.citation: Z Hautkr. 1985 Nov 15;60(22):1817-8
references.pmid: 3909674
references.citation: Antiviral Res. 1986 May;6(3):151-9
references.pmid: 3015019
references.citation: Clin Infect Dis. 2008 Sep 1;47(5):651-8
references.pmid: 18637755
references.citation: N Engl J Med. 1984 Jun 14;310(24):1545-50
references.pmid: 6328297
references.citation: Sex Transm Dis. 1988 Jan-Mar;15(1):58-62
references.pmid: 3282336
references.citation: N Engl J Med. 2004 Jan 1;350(1):11-20
references.pmid: 14702423
references.citation: J Infect Dis. 1989 May;159(5):845-50
references.pmid: 2540245
references.citation: J Med Virol. 1993;Suppl 1:45-50
references.pmid: 8245892
references.citation: Arch Dermatol. 1993 May;129(5):582-7
references.pmid: 8481018
references.citation: Trans Assoc Am Physicians. 1983;96:278-83
references.pmid: 6388102
references.citation: J Infect Dis. 1994 Jun;169(6):1338-41
references.pmid: 8195614
references.citation: Mayo Clin Proc. 2006 Oct;81(10):1321-7
references.pmid: 17036557
references.citation: Sex Transm Infect. 1999 Dec;75(6):398-402
references.pmid: 10754944
references.citation: Ann Intern Med. 1994 Dec 1;121(11):847-54
references.pmid: 7978697
references.citation: Pediatrics. 2013 Feb;131(2):e635-46
references.pmid: 23359576
references.citation: Genitourin Med. 1992 Oct;68(5):312-6
references.pmid: 1385295
references.citation: J Clin Epidemiol. 2011 Feb;64(2):163-71
references.pmid: 20688472
references.citation: Stat Med. 2002 Aug 15;21(15):2145-59
references.pmid: 12210630
references.citation: BMC Med Res Methodol. 2009 Jan 12;9:2
references.pmid: 19138428
references.citation: Stat Med. 2004 Oct 30;23(20):3105-24
references.pmid: 15449338
references.citation: J Infect Dis. 2004 Oct 15;190(8):1374-81
references.pmid: 15378428
references.citation: N Engl J Med. 2004 May 6;350(19):1970-7
references.pmid: 15128897
references.citation: Bull World Health Organ. 2004 Jun;82(6):447-53
references.pmid: 15356938
references.citation: J Am Acad Dermatol. 2007 Aug;57(2):238-46
references.pmid: 17416440
references.citation: Lancet. 2001 May 12;357(9267):1513-8
references.pmid: 11377626
references.citation: BMJ. 2007 May 19;334(7602):1048-52
references.pmid: 17510153
references.citation: Arch Dermatol. 1998 Feb;134(2):185-91
references.pmid: 9487210
references.citation: Genitourin Med. 1989 Apr;65(2):103-5
references.pmid: 2473952
references.citation: Biostatistics. 2011 Jan;12(1):122-42
references.pmid: 20656692
references.citation: Acta Derm Venereol. 1985;65(1):59-63
references.pmid: 2578707
references.citation: J Antimicrob Chemother. 2011 Nov;66(11):2593-600
references.pmid: 21865349
references.citation: N Engl J Med. 1984 Jun 14;310(24):1551-6
references.pmid: 6328298
references.citation: Obstet Gynecol. 1989 Jan;73(1):84-7
references.pmid: 2642329
references.citation: J Clin Virol. 2008 Oct;43(2):190-5
references.pmid: 18621575
references.citation: Br J Pharmacol. 2006 Jan;147(1):1-11
references.pmid: 16284630
references.citation: BMC Med. 2012 Jul 04;10:68
references.pmid: 22762722
references.citation: Brain Behav Immun. 2011 Oct;25(7):1475-81
references.pmid: 21693182
references.citation: J Infect Dis. 1988 Dec;158(6):1227-34
references.pmid: 2848900
references.citation: AIDS. 2000 Jun 16;14(9):1211-7
references.pmid: 10894286
references.citation: JAMA. 1988 Jul 8;260(2):201-6
references.pmid: 3290517
references.citation: Clin Infect Dis. 2002 Apr 1;34(7):958-62
references.pmid: 11880962
references.citation: J Infect Dis. 1988 Mar;157(3):588-93
references.pmid: 2830348
references.citation: Genitourin Med. 1985 Dec;61(6):387-90
references.pmid: 3910546
references.citation: Qual Life Res. 2006 Aug;15(6):1043-52
references.pmid: 16900284
references.citation: Am J Med. 1988 Aug 29;85(2A):20-5
references.pmid: 3044086
references.citation: Curr Med Res Opin. 2009 Feb;25(2):483-7
references.pmid: 19192993
references.citation: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004946
references.pmid: 18254066
references.citation: Sex Transm Dis. 2006 Sep;33(9):529-33
references.pmid: 16540883
references.citation: Sex Transm Dis. 2008 Feb;35(2):124-8
references.pmid: 17921912
references.citation: J Int Med Res. 1994;22 Suppl 1:24A-31A; discussion 31A-32A
references.pmid: 8063021
references.citation: AIDS. 2006 Jan 2;20(1):73-83
references.pmid: 16327322
references.citation: Ann Intern Med. 1996 Jan 1;124(1 Pt 1):8-15
references.pmid: 7503497
references.citation: JAMA. 1984 Apr 27;251(16):2103-7
references.pmid: 6368877
references.citation: J Infect Dis. 2005 Sep 15;192(6):1102-7
references.pmid: 16107966
references.citation: J Cutan Med Surg. 2003 Nov-Dec;7(6):449-54
references.pmid: 15931690
references.citation: Genitourin Med. 1997 Apr;73(2):105-9
references.pmid: 9215091
references.citation: MMWR Morb Mortal Wkly Rep. 2010 Apr 23;59(15):456-9
references.pmid: 20414188
references.citation: Sex Transm Infect. 2002 Jun;78(3):160-5
references.pmid: 12238644
references.citation: J Med Virol. 1988 Sep;26(1):33-9
references.pmid: 3183633
references.citation: BMJ. 2007 Nov 3;335(7626):914-6
references.pmid: 17974687
references.citation: JAMA. 2011 Apr 13;305(14):1441-9
references.pmid: 21486977